|
刘林芹.帕金森病患者血清CXC型趋化因子配体16、锌α2糖蛋白表达与疾病分期、认知障碍相关[J].内科急危重症杂志,2025,31(3):244-247
|
| DOI：10.11768/nkjwzzzz20250310 |
| 中文关键词: 帕金森病 CXC型趋化因子配体16 锌α2糖蛋白 疾病分期 认知障碍 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 61 |
| 全文下载次数: 64 |
| 中文摘要: |
| 摘要 目的：探讨帕金森病患者血清CXC型趋化因子配体16（CXCL16）、锌α2糖蛋白（ZAG）与疾病分期、认知障碍的关系。方法：选取住院治疗的118例帕金森病患者为研究组，根据Hoehn-Yahr(H-Y)分级系统将其分为早期组（43例）、中期组（49例）及晚期组（26例），再根据简易智力状态检查评分（MMSE)将研究组分为认知障碍组（72例）及认知正常组（46例），另选取同期健康体检者118例为对照组。采用酶联免疫吸附法（ELISA）检测血清CXCL16、ZAG表达水平；采用Spearman法分析患者血清CXCL16、ZAG水平与疾病分期、认知障碍相关性；运用Logistic回归分析影响帕金森病的相关因素。结果：与对照组比较，帕金森病患者血清CXCL16水平明显较高，ZAG水平明显较低（P均＜0.05）；早期组血清CXCL16水平显著低于中、晚期组，且中期组低于晚期组，而早期组血清ZAG水平显著高于中、晚期组，且中期组高于晚期组（P均＜0.05）；与认知正常组比较，认知障碍组血清CXCL16表达水平更高，血清ZAG表达水平更低（P均＜0.05）；经Spearman等级相关分析显示，血清CXCL16与疾病分期、认知障碍呈正相关，血清ZAG与疾病分期、认知障碍呈负相关（P均＜0.05）；Logistic回归分析结果显示，血清CXCL16、ZAG是帕金森病的影响因素（P均＜0.05）。结论：帕金森病患者血清CXCL16、ZAG水平与疾病分期、认知障碍紧密联系，且血清CXCL16、ZAG是帕金森病的影响因素。 |
| 英文摘要: |
| Abstract Objective: To explore the relationship between serum CXC type chemokine ligand 16 (CXCL16) and zinc α2 glycoprotein (ZAG) levels in patients with Parkinson's disease and disease staging and cognitive impairment. Methods: A total of 118 patients with Parkinson's disease who were hospitalized were selected as the study group, and then divided into early group (43 cases), middle group (49 cases) and late group (26 cases) according to different disease stages, and the study group was divided into cognitive impairment group (72 cases) and normal cognitive group (46 cases) according to cognitive status. A total of 118 individuals who underwent health examinations in our hospital during the same period served as the control group. The expression levels of CXCL16 and ZAG in serum were detected by enzyme-linked immunosorbent assay (ELISA). Spearman method was applied to analyze the correlation between serum CXCL16 and ZAG expression levels, disease stage, and cognitive impairment in patients with Parkinson's disease. Logistic regression was applied to analyze the relevant factors affecting Parkinson's disease. Results: Compared with the control group, the expression level of serum CXCL16 in patients with Parkinson's disease was obviously increased, while the expression level of ZAG was obviously reduced (all P< 0.05). The serum CXCL16 level in the early group was significantly lower than that in the middle and late groups, and that in the middle group was lower than that in the late group. The serum ZAG level in the early group was significantly higher than that in the middle and late groups, and that in the middle group was higher than in the late group (all P< 0.05). Compared with the normal group, the expression level of CXCL16 increased and ZAG decreased in the cognitive impairment group (all P< 0.05). Spearman rank correlation analysis showed that serum CXCL16 was positively correlated with disease stage and cognitive impairment, while serum ZAG was negatively correlated with disease stage and cognitive impairment (all P< 0.05). The results of Logistic regression analysis showed that serum CXCL16 and ZAG were influencing factors for Parkinson's disease (all P< 0.05). Conclusion: The expression levels of serum CXCL16 and ZAG in patients with Parkinson's disease are closely related to disease stage and cognitive impairment, and serum CXCL16 and ZAG are influencing factors for Parkinson's disease. |
|
|
|
|
